Archive | 2021

Atezolizumab Caused Pityriasis Lichenoides-Like Drug Eruption Treated with Narrowband Ultraviolet B



Pityriasis lichenoides is a rare cutaneous disease that exists along a spectrum with acute and chronic features. The acute form, pityriasis lichenoides et varioliformis acuta (PLEVA), presents as a sudden onset scaly, erythematous, pruritic eruption while the chronic form, pityriasis lichenoides chronica, presents similarly but with a more indolent course. This inflammatory condition can have numerous triggers, including infections and medications. However, checkpoint inhibitors, despite being associated with a wide variety of cutaneous adverse events, have only rarely been associated with a pityriasis lichenoides-like eruption. We report a case of drug-induced pityriasis lichenoides-like eruption secondary to checkpoint inhibitor atezolizumab that was successfully treated with narrowband ultraviolet B (NBUVB) light. To our knowledge, this is the first case of an immune checkpoint inhibitor induced pityriasis lichenoides which responded well to NBUVB.

Volume 5
Pages 143-146
DOI 10.25251/SKIN.5.2.10
Language English
Journal None

Full Text